No abstract

No abstract

A new implant Ti-7Al-3V-2Mo-2Fe alloy was elaborated and its behaviour in Ringer-Brown and Ringer solutions (of different pH values) was studied using cyclic potentiodynamic and linear polarisation, electrochemical impedance spectroscopy (EIS) and scanning electron microscopy (SEM) with its link energy dispersive X-ray system (EDX). Cyclic potentiodynamic polarisation curves revealed that the Ti-7Al-3V-2Mo-2Fe alloy is self-passivated in Ringer solutions. Pitting corrosion appeared in alkaline Ringer solution but at very electropositive values of the breakdown and pitting protection potentials and it is not possible to develop local corrosion on this alloy, even in extreme functional conditions. EIS spectra at open circuit potential exhibited two phase angles characterising a resistant passive film and some charge transfer reactions. SEM-EDX analysis shows the presence of some aggregates containing complex compounds of calcium, magnesium, phosphor, silicon deposited on the alloy surface.

No abstract

The aim of the present paper is to apply the mechanical alloying process to obtain from powder components a new biodegradable Mg-based alloy powder from the system Mg-xZn-Zr-Ca, with high biomechanical and biochemical performance. Various processing parameters for mechanical alloying have been experimented with the ultimate goal to establish an efficient processing route for the production of small biodegradable parts for the medical domain. It has been observed that for the same milling parameters, the composition of the powders has influenced the powder size and shape. On the other hand, for the same composition, the highest experimented milling speed and time conduct to finer powder particles, almost round-shaped, without pores or various inclusions. The most uniform size has been obtained for the powder sample with 10 wt.%Zn. These powders were finally processed by selective laser melting, an additive manufacturing technology, to obtain a homogeneous experimental sample, without cracking, for future more systematical trials.